EVGN logo

EVOGENE LTD

EVGNNASDAQ
πŸ† #5121 by market capEarnings Nov 18US Equity
$0.36β–Ό $0.01 (βˆ’1.87%)
Market closed Β· at close
πŸ””
Track EVGN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.9%
7dβ–Ό 4.3%
14dβ–Ό 6.2%
30dβ–Ό 10.6%
ytdβ–Ό 66.7%
1yβ–Ό 71.9%
🏦Market Cap
$3M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-30.9%
Declining
πŸ“ŠGross Margin
-14.2%
Thin
πŸ’΅FCF Margin
-910.0%
Thin
βš–οΈP/S Ratio
2.5x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.36 – $0.36
52-Week Range
$0.35 – $1.33
Volume (shares)
551
Avg Volume (shares)
β€”
Shares Outstanding
8.6M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$347,000
P/E Ratio
-0.4
P/S Ratio
2.5x
EPS (TTM)
$-0.75
Dividend Yield
0.00%
Dilution (1yr)
+28.3%
EVGN logo

EVOGENE LTD

EVGN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4Mβ–Ό βˆ’30.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-6.3%β–Ό βˆ’110.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$14Mβ–Ό βˆ’25.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$14Mβ–Ό βˆ’32.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.7Mβ–² +28.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11Mβ–² +$8M YoY
StockOtter Β· stockotter.space

About EVOGENE LTD

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.